Cancer CDK Inhibitors Market - Global Outlook and Forecast 2022-2028

January 2022 | 69 pages | ID: C55CD4A23EA9EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Cancer CDK Inhibitors in Global, including the following market information:

Global Cancer CDK Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cancer CDK Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Preclinical Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cancer CDK Inhibitors include Pfizer, Sanofi, Merck, Eli-Lilly, Bayer Pharmaceuticals, Syros Pharmaceuticals, Amgen and Cyclacel Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer CDK Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cancer CDK Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cancer CDK Inhibitors Market Segment Percentages, by Type, 2021 (%)

• Preclinical
• Phase-I
• Phase-I/II
• Phase-II
• Phase-III

Global Cancer CDK Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cancer CDK Inhibitors Market Segment Percentages, by Application, 2021 (%)

• Medical Institution
• Scientific Research Center

Global Cancer CDK Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cancer CDK Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cancer CDK Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cancer CDK Inhibitors revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Sanofi
• Merck
• Eli-Lilly
• Bayer Pharmaceuticals
• Syros Pharmaceuticals
• Amgen
• Cyclacel Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cancer CDK Inhibitors Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cancer CDK Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CANCER CDK INHIBITORS OVERALL MARKET SIZE

2.1 Global Cancer CDK Inhibitors Market Size: 2021 VS 2028
2.2 Global Cancer CDK Inhibitors Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cancer CDK Inhibitors Players in Global Market
3.2 Top Global Cancer CDK Inhibitors Companies Ranked by Revenue
3.3 Global Cancer CDK Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 Cancer CDK Inhibitors Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cancer CDK Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cancer CDK Inhibitors Players in Global Market
  3.6.1 List of Global Tier 1 Cancer CDK Inhibitors Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cancer CDK Inhibitors Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Cancer CDK Inhibitors Market Size Markets, 2021 & 2028
  4.1.2 Preclinical
  4.1.3 Phase-I
  4.1.4 Phase-I/II
  4.1.5 Phase-II
  4.1.6 Phase-III
4.2 By Type - Global Cancer CDK Inhibitors Revenue & Forecasts
  4.2.1 By Type - Global Cancer CDK Inhibitors Revenue, 2017-2022
  4.2.2 By Type - Global Cancer CDK Inhibitors Revenue, 2023-2028
  4.2.3 By Type - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cancer CDK Inhibitors Market Size, 2021 & 2028
  5.1.2 Medical Institution
  5.1.3 Scientific Research Center
5.2 By Application - Global Cancer CDK Inhibitors Revenue & Forecasts
  5.2.1 By Application - Global Cancer CDK Inhibitors Revenue, 2017-2022
  5.2.2 By Application - Global Cancer CDK Inhibitors Revenue, 2023-2028
  5.2.3 By Application - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cancer CDK Inhibitors Market Size, 2021 & 2028
6.2 By Region - Global Cancer CDK Inhibitors Revenue & Forecasts
  6.2.1 By Region - Global Cancer CDK Inhibitors Revenue, 2017-2022
  6.2.2 By Region - Global Cancer CDK Inhibitors Revenue, 2023-2028
  6.2.3 By Region - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Cancer CDK Inhibitors Revenue, 2017-2028
  6.3.2 US Cancer CDK Inhibitors Market Size, 2017-2028
  6.3.3 Canada Cancer CDK Inhibitors Market Size, 2017-2028
  6.3.4 Mexico Cancer CDK Inhibitors Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Cancer CDK Inhibitors Revenue, 2017-2028
  6.4.2 Germany Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.3 France Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.4 U.K. Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.5 Italy Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.6 Russia Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.7 Nordic Countries Cancer CDK Inhibitors Market Size, 2017-2028
  6.4.8 Benelux Cancer CDK Inhibitors Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Cancer CDK Inhibitors Revenue, 2017-2028
  6.5.2 China Cancer CDK Inhibitors Market Size, 2017-2028
  6.5.3 Japan Cancer CDK Inhibitors Market Size, 2017-2028
  6.5.4 South Korea Cancer CDK Inhibitors Market Size, 2017-2028
  6.5.5 Southeast Asia Cancer CDK Inhibitors Market Size, 2017-2028
  6.5.6 India Cancer CDK Inhibitors Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Cancer CDK Inhibitors Revenue, 2017-2028
  6.6.2 Brazil Cancer CDK Inhibitors Market Size, 2017-2028
  6.6.3 Argentina Cancer CDK Inhibitors Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cancer CDK Inhibitors Revenue, 2017-2028
  6.7.2 Turkey Cancer CDK Inhibitors Market Size, 2017-2028
  6.7.3 Israel Cancer CDK Inhibitors Market Size, 2017-2028
  6.7.4 Saudi Arabia Cancer CDK Inhibitors Market Size, 2017-2028
  6.7.5 UAE Cancer CDK Inhibitors Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Cancer CDK Inhibitors Major Product Offerings
  7.1.4 Pfizer Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Sanofi
  7.2.1 Sanofi Corporate Summary
  7.2.2 Sanofi Business Overview
  7.2.3 Sanofi Cancer CDK Inhibitors Major Product Offerings
  7.2.4 Sanofi Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.2.5 Sanofi Key News
7.3 Merck
  7.3.1 Merck Corporate Summary
  7.3.2 Merck Business Overview
  7.3.3 Merck Cancer CDK Inhibitors Major Product Offerings
  7.3.4 Merck Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.3.5 Merck Key News
7.4 Eli-Lilly
  7.4.1 Eli-Lilly Corporate Summary
  7.4.2 Eli-Lilly Business Overview
  7.4.3 Eli-Lilly Cancer CDK Inhibitors Major Product Offerings
  7.4.4 Eli-Lilly Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.4.5 Eli-Lilly Key News
7.5 Bayer Pharmaceuticals
  7.5.1 Bayer Pharmaceuticals Corporate Summary
  7.5.2 Bayer Pharmaceuticals Business Overview
  7.5.3 Bayer Pharmaceuticals Cancer CDK Inhibitors Major Product Offerings
  7.5.4 Bayer Pharmaceuticals Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.5.5 Bayer Pharmaceuticals Key News
7.6 Syros Pharmaceuticals
  7.6.1 Syros Pharmaceuticals Corporate Summary
  7.6.2 Syros Pharmaceuticals Business Overview
  7.6.3 Syros Pharmaceuticals Cancer CDK Inhibitors Major Product Offerings
  7.6.4 Syros Pharmaceuticals Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.6.5 Syros Pharmaceuticals Key News
7.7 Amgen
  7.7.1 Amgen Corporate Summary
  7.7.2 Amgen Business Overview
  7.7.3 Amgen Cancer CDK Inhibitors Major Product Offerings
  7.7.4 Amgen Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.7.5 Amgen Key News
7.8 Cyclacel Pharmaceuticals
  7.8.1 Cyclacel Pharmaceuticals Corporate Summary
  7.8.2 Cyclacel Pharmaceuticals Business Overview
  7.8.3 Cyclacel Pharmaceuticals Cancer CDK Inhibitors Major Product Offerings
  7.8.4 Cyclacel Pharmaceuticals Cancer CDK Inhibitors Revenue in Global Market (2017-2022)
  7.8.5 Cyclacel Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cancer CDK Inhibitors Market Opportunities & Trends in Global Market
Table 2. Cancer CDK Inhibitors Market Drivers in Global Market
Table 3. Cancer CDK Inhibitors Market Restraints in Global Market
Table 4. Key Players of Cancer CDK Inhibitors in Global Market
Table 5. Top Cancer CDK Inhibitors Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cancer CDK Inhibitors Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cancer CDK Inhibitors Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cancer CDK Inhibitors Product Type
Table 9. List of Global Tier 1 Cancer CDK Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer CDK Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cancer CDK Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cancer CDK Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cancer CDK Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Cancer CDK Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cancer CDK Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cancer CDK Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Cancer CDK Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cancer CDK Inhibitors Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cancer CDK Inhibitors Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cancer CDK Inhibitors Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cancer CDK Inhibitors Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cancer CDK Inhibitors Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cancer CDK Inhibitors Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cancer CDK Inhibitors Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Cancer CDK Inhibitors Product Offerings
Table 32. Pfizer Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 33. Sanofi Corporate Summary
Table 34. Sanofi Cancer CDK Inhibitors Product Offerings
Table 35. Sanofi Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 36. Merck Corporate Summary
Table 37. Merck Cancer CDK Inhibitors Product Offerings
Table 38. Merck Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 39. Eli-Lilly Corporate Summary
Table 40. Eli-Lilly Cancer CDK Inhibitors Product Offerings
Table 41. Eli-Lilly Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 42. Bayer Pharmaceuticals Corporate Summary
Table 43. Bayer Pharmaceuticals Cancer CDK Inhibitors Product Offerings
Table 44. Bayer Pharmaceuticals Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 45. Syros Pharmaceuticals Corporate Summary
Table 46. Syros Pharmaceuticals Cancer CDK Inhibitors Product Offerings
Table 47. Syros Pharmaceuticals Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 48. Amgen Corporate Summary
Table 49. Amgen Cancer CDK Inhibitors Product Offerings
Table 50. Amgen Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)
Table 51. Cyclacel Pharmaceuticals Corporate Summary
Table 52. Cyclacel Pharmaceuticals Cancer CDK Inhibitors Product Offerings
Table 53. Cyclacel Pharmaceuticals Cancer CDK Inhibitors Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Cancer CDK Inhibitors Segment by Type in 2021
Figure 2. Cancer CDK Inhibitors Segment by Application in 2021
Figure 3. Global Cancer CDK Inhibitors Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Cancer CDK Inhibitors Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cancer CDK Inhibitors Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cancer CDK Inhibitors Revenue in 2021
Figure 8. By Type - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 12. US Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 16. Germany Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 17. France Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 24. China Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 28. India Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 30. Brazil Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cancer CDK Inhibitors Revenue Market Share, 2017-2028
Figure 33. Turkey Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cancer CDK Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sanofi Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli-Lilly Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bayer Pharmaceuticals Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Syros Pharmaceuticals Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Amgen Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cyclacel Pharmaceuticals Cancer CDK Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)